We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/ II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120 mg/m 2 per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for CD20 + lymphoma) used in the (R)ICE regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (MTD) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty-eight patients were treated of which 71% had refractory disease. No dose-limiting toxicities were observed. The recommended phase II dose of bendamustine was 120 mg/m 2 per day on days 1 and 2. Response rates were 85% (70% complete response, CR) in HL, and 65% (40% CR) in DLBCL. Stem cell collection was successful in 30 of 32 patients. The most common non-haematological toxicities ≥grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)EC regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to RICE, offering an effective outpatient treatment option for patients with relapsed or refractory DLBCL and HL.
Lymphoma is the seventh most common cancer in the United
States with approximately 80 500 new cases in 2017 (Siegel et al, 2017) . Though most patients with aggressive lymphoma, such as diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin Lymphoma (HL), will be cured with frontline treatment, the standard treatment for relapsed or refractory disease is salvage therapy followed by autologous stem cell transplantation (ASCT) if remission can be attained (Colpo et al, 2012; Nademanee & Forman, 2006) . A number of factors are predictive of improved outcomes following ASCT, with some of the most important predictors including chemosensitivity, disease bulk at the time of transplant and patient's overall performance status (Nademanee & Forman, 2006 ). An ideal salvage regimen would yield high response rates, provide a successful platform from peripheral blood stem cell (PBSC) mobilization, and be safely administered in an outpatient setting without compromising performance status.
Bendamustine is a unique cytotoxic agent with a hybrid mode of action. It has both alkylating and antimetablolite properties due to its structural similarities to alkylating research paper agents and purine analogues. Its single-agent clinical activity has been demonstrated in a wide variety of haematological malignancies including indolent non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), HL and multiple myeloma. Both preclinical and clinical studies have revealed incomplete cross-resistance between bendamustine and conventional alkylating agents (Chow et al, 2001; Cheson & Rummel, 2009) . It is also active in primary NHL cells refractory to doxorubicin and etoposide (Leoni & Hartley, 2011) . Several clinical trials using the combination of rituximab and bendamustine (BR) in patients with untreated (Rummel et al, 2013) , or relapsed/refractory indolent NHL and mantle cell lymphoma (MCL) (Rummel et al, 2005; Robinson et al, 2008) have consistently reported a favourable safety profile and encouraging overall response rate (ORR). Bendamustine as a single agent has also demonstrated impressive anti-lymphoma activities in patients with recurrent HL with ORR as high as 55% (Moskowitz et al, 2013) . Importantly, bendamustine has a moderate non-haematological toxicity profile and is well tolerated as a single agent or combined with other chemotherapeutic agents (Cheson & Leoni, 2011) . Based on these above features of bendamustine, we hypothesized that bendamustine could safely and effectively replace ifosfamide in the commonly used (R)ICE (rituximab (for B cell lymphoma), ifosfomide, carboplatin and etoposide) regimen and carried out a phase 1/2 clinical trial to evaluate this novel combination in patients with relapsed or refractory DLBCL and classic HL. We also quantified the ability to collect autologous peripheral stem cells following this regimen, as this treatment was intended to serve as a bridge to transplantation for patients who are eligible for ASCT.
Methods and materials

Study design
This was an open-label, multicentre, dose escalation phase I/ II study with disease-specific expansion cohorts combining bendamustine with rituximab (in CD20 + lymphoma), carboplatin and etoposide in patients with relapsed or refractory lymphoma. Bendamustine was supplied by Teva Inc. (North Wales, PA). The primary objectives were to estimate the maximally tolerated dose (MTD) of bendamustine in the T (R)EC combination (bendamustine, rituximab, carboplatin and etoposide), and determine the safety and tolerability of this outpatient regimen. Secondary objectives were to describe the efficacy of T(R)EC and determine the ability to proceed to peripheral blood stem cell collection following the above regimen. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. All authors and study coordinators analysed the data. All authors have access to primary clinical trial data. A total of 14 centres, including 12 community practice sites, participated in the study. The protocol was approved by the institutional review board of each participating centre and all participants gave written consent. This trial was registered at ClinicalTrials.gov (NCT01165112). Eligible patients had histologically-confirmed relapsed or refractory DLBCL or HL. Patients with other lymphoid malignancies were eligible for the dose escalation portion of the study with protocol chair review and approval. Patients were required to have measurable disease, age ≥18 years, an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2, absolute neutrophil count (ANC) ≥1Á5 9 10 9 /l, platelet count ≥100 9 10 9 /l, serum creatinine ≤132Á6 lmol/l or creatinine clearance ≥50 ml/min, total bilirubin ≤1Á5 times upper limit of normal (ULN), aspartate transaminase and alanine transaminase <2Á5 times ULN.
Patients were excluded if they had known human immunodeficiency virus or active Hepatitis B virus infection, active central nervous system disease, were pregnant or nursing, had prior malignancies within 5 years, had lymphoma refractory to a regimen containing carboplatin, cisplatin, ifosfamide or etoposide, had prior treatment with bendamustine, had pelvic radiation within 12 months or received more than 2 prior therapies with myelotoxic regimens, active infection, active cardiac disease, a left ventricular ejection fraction <50%, autologous or allogeneic transplantation within 12 months, or radioimmunotherapy within 6 months.
Procedures
Each 21-day cycle consisted of bendamustine given intravenously (iv) at a dose ranging from 60 to 120 mg/m 2 daily on days 1 and 2, carboplatin dosed at an area under the curve of 5 (capped at 800 mg) iv over 1 h on day 1, and etoposide 100 mg/m 2 iv over 1 h on days 1-3. Patients with CD20 + lymphoma also received one dose of rituximab 375 mg/m 2 each cycle. No intrapatient bendamustine dose modification was allowed. Standard dose adjustments for carboplatin and etoposide during treatment were allowed. All therapy was administered as an outpatient. Filgrastim at ≥5 lg/kg per day until neutrophil recovery, or pegfilgrastim 6 mg 9 1 given 24-72 h after chemotherapy completion was required. The second cycle was not initiated until the ANC was ≥1 9 10 9 /l and the platelet count was ≥50 9 10 9 /l. Therapy could be delayed for a maximum of 3 weeks. Patients received treatment for up to 2 cycles. Adverse events (AEs) were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (http://ctep.cancer.gov/pro tocolDevelopment/electronic_applications/docs/ctcaev4.pdf). Dose-limiting toxicities (DLTs) were defined as: (1) any nonhaematological grade 4 or 5 NCI CTCAE adverse event that is possibly, probably or definitely related to the drug combination within 28 days of the last dose of the study drug; (2) the patient did not complete one full cycle of therapy due to toxicity from the treatment, and (3) any serious AE that is possibly, probably or definitely related to the drug combination, but does not meet the criteria above for a DLT, could be considered a DLT at the discretion of the study team.
Clinical response assessments
All patients were evaluated before and after treatment with a history and physical examination, laboratory tests including complete blood count, comprehensive metabolic panel, lactate dehydrogenase, diagnostic computed tomography (CT) and positron emission tomography (PET) scan. Bone marrow biopsy was performed at baseline and post-treatment if the baseline study showed disease involvement. Responses were determined according to the 2007 International Workshop NHL criteria (Cheson et al, 2007) .
Statistical design and analysis
Bendamustine was escalated or de-escalated following the 'two-stage' design (Storer, 2001) . During stage 1, cohorts of single patients were treated at each dose level starting at 60 mg/m 2 9 2 days (level 1). Once a DLT was observed or the highest dose level was reached, stage 1 was complete. Stage 2 began with a cohort of 4 patients entered at one lower dose level than the final dose level of stage 1 if there was DLT or the final dose level if there was no DLT. Subsequent cohorts of 4 patients were entered with doses escalated, maintained or deescalated if 0, 1 or ≥2 DLTs, respectively, were observed. These rules were followed until 20 patients had been treated in stage 2. A dose-toxicity curve was generated to estimate the MTD/ phase II dose (RP2D). The MTD/RP2D dose was pre-specified as the dose of bendamustine in the T(R)EC chemotherapy yielding a DLT rate of ≤25%. When stage 2 was completed, a phase 2 portion was started to treat a minimum of 20 DLBCL and 20 HL patients evaluable for response. The tested regimen would be deemed as potentially efficacious and worthy of further study if the observed response rates meet or exceed 55% in DLBCL or 85% in HL.
Results
Patient characteristics
Forty-eight patients were enrolled between October 2010 and April 2015 at the University of Washington (UW)-Fred Hutchinson Cancer Research Center (n = 26), UW-Harborview Medical Center (n = 1) and 12 community sites (n = 22). Patient baseline characteristics are summarized in Table I . The median age was 51 years; 31% of the patients were aged 60 years or older. Lymphoma histologies included: HL in 21 patients, DLBCL in 20, MCL in 2, transformed mycosis fungoides (t-MF) in 2, follicular lymphoma (FL) in 2, and lymphoplasmacytic lymphoma (LPL) in one. The median number of prior regimens was 1 (range 0-4). All except two MCL patients had at least one prior treatment.
Seventy-one percent of the patients had refractory disease with less than a partial response to their last therapy or a response duration of less than 6 months, including 71% HL and 75% DLBCL patients with primary refractory disease.
Treatment, dose escalation and MTD/RP2D determination Figure 1 illustrates the progress of the study. Four patients were treated in stage 1 and 44 patients were treated in the stage 2 and phase 2 portions. The bendamustine dose was escalated in combination with standard doses of rituximab (for CD20 + disease only), carboplatin and etoposide used in the (R)ICE regimen from dose level 1 (60 mg/m 2 daily 9 2) to level 4 (120 mg/m 2 daily 9 2) in stage 1 with no a single DLT observed. None of the 20 patients treated at dose level 4 in Stage 2 exhibited a DLT. Therefore, no MTD was reached and dose level 4 was determined to be the RP2D. The phase 2 portion was completed with an additional 24 patients. A total of 20 patients with DLBCL and 21 patients with HL were treated. All except one patient with HL were treated at dose level 4, the RP2D level.
Response and survival
Forty-eight patients received study treatment and 47 were evaluable for response assessment. One patient with HL was not evaluable due to lack of proper post-therapy staging. Responses were observed in 33 patients (70%) with 22 (47%) attaining a complete response (CR). Two MCL and 1 FL patients achieved PR. In the HL cohort, the overall response rate (ORR) was 85% with 14 (70%) CR and 3 (15%) PR. CR was seen in 67% of HL patients with relapsed disease and 71% with primary-refractory disease. One HL patient with disease progression following brentuximab treatment achieved CR. Nineteen of 20 evaluable patients experienced tumour reduction (Fig 2A) . In the DLBCL cohort, the ORR was 65% with 8 (40%) CR and 5 (25%) PR. Responses were seen in 5/5 (100%) with relapsed disease and 8/15 (53%) with primary refractory disease. Seventeen of 20 patients experienced tumour reduction (Fig 2B) . OS and PFS are shown in Fig 3. The median follow-up for surviving patients was 19Á9 (range, 5Á7-54Á4) months. The median PFS was 12Á4 months. All patients except one undergoing PBSC transplantation remained in remission and alive throughout the follow-up period.
Toxicity, treatment completion, and delays
There were no treatment-related deaths. No patient experienced any DLT at any dose level across 95 delivered cycles of therapy. The most common treatment related haematological grade 3 and above AE was thrombocytopenia, seen in 63% of patients with all but one recovering platelet counts of 50 9 10 9 /l by the end of each 21-day cycle. The most
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common treatment-related non-haematological grade 3 and above AEs were febrile neutropenia (n = 4, 8%) and dehydration (n = 4, 8%). Table II summarizes all AEs graded 3 and above. Forty-seven (98%) patients completed the planned 2 cycles of treatment. One patient with t-MF did not receive cycle 2 due to disease progression. Five of the 95 cycles (5%) were delayed. The longest delay was 2 weeks in a patient who developed aseptic meningitis during cycle 1. The causes for the delay of other four cycles were upper respiratory infection, neutropenia, deconditioning, and 7-day prolonged thrombocytopenia, respectively.
Stem cell mobilization and collection, transplant realization, and engraftment
We also evaluated the ability to mobilize and collect autologous PBSC after receiving treatment on this study. PBSC harvest was successful in 30 of 32 patients who attempted this procedure immediately following T(R)EC, with a median collection of 5Á38 9 10 6 CD34 + cells/kg (range, 3Á20-19Á20 9 10 6 ). One patient's collection was aborted due to onset of infection. The second patient failed an initial attempt and didn't collect after a second chemomobilization. The patient had a prior history of CLL and prostate cancer with prior pelvic radiation therapy. Three of five patients underwent successful PBSC mobilization and collection after a subsequent regimen after T(R)EC treatment. Of the 33 responders, 20 (60%) proceeded directly to transplant (Fig 1) ; 13 patients did not proceed to transplant because of transplant ineligibility (n = 5), additional treatment prior to ASCT (n = 5), insurance denial (n = 1), patient choice 17 100 *Defined as less than a partial response to the last prior regimen. †Defined as less than a complete response to the last prior regimen or relapse within 6 months of completion of initial therapy. (n = 1) and stem cell collection failure (n = 1). All transplanted patients engrafted and the time to neutrophil and platelet engraftment was comparable to other chemotherapybased mobilization regimens (data not shown).
Discussion
This phase 1/2 trial demonstrated that the combination of bendamustine, rituximab (in CD20 + disease), etoposide and carboplatin is extremely well tolerated. No patients experienced any DLT or treatment-related deaths. Forty-five of 48 patients were treated at dose level 4, the highest dose level and RP2D with bendamustine given at 120 mg/m 2 on days 1 and 2. We opted not to further escalate the dosing to identify a true MTD as dose level 4 is the highest US Food and Drug Administration (FDA) approved dose for bendamustine used as single agent, although it is possible that further dose escalation could have further increased the response rate. Febrile neutropenia accounted for the highest grade 3 and above AE (8%). Unlike gemcitabine or brentuximab vedotin (BV)-containing regimens, neither lung toxicity nor peripheral neuropathy was observed with this regimen. Our study is limited by the single arm design and modest sample size. Nevertheless, the T(R)EC regimen is active in treating patients with relapsed and refractory HL and DLBCL. Although 71% of the participants had chemo-refractory disease, two cycles of T(R)EC led to ORR and CR rates of 85% and 70% in the HL cohort; and 65% and 40% in the DLBCL cohort. These response rates met the pre-set efficacy endpoint (≥85% for HL and ≥55% for DLBCL) and hence the regimen is deemed as potentially efficacious and worthy of further study. Despite receiving only 2 cycles, the efficacy is similar to that of 4 cycles of bendamustine, gemcitabine and vinorelbine (BeGEV) (83% ORR; 73% CR) (Santoro et al, 2016) and to that of up to 6 cycles of bendamustine and brentuximab (93% ORR; 74% CR) (LaCasce et al, 2015) . It also compares favourably to that of 2 cycles of GDP (gemcitabine, dexamethasone and cisplatin), an outpatient salvage regimen which produced a response rate of 45Á2% in similar patient population (Crump et al, 2014) . ICE or RICE regimen are the most commonly used salvage regimens in patients with relapsed and refractory lymphoma. Two cycles of ICE for relapsed HL produces complete remission ranging from 26% (response evaluated by CT) to 61% (Moskowitz et al, 2001 (Moskowitz et al, , 2012 . Three cycles of RICE treatment resulted in 51% ORR in patients with recurrent DLBCL and with prior rituximab exposure (Gisselbrecht et al, 2010) . Therefore, T(R)EC also compares favourably to (R)ICE for patients with HL or DLBCL, although our patients only received 2 cycles. It is encouraging that one HL patient whose disease was refractory to BV achieved CR after 2 cycles of TEC. BV is FDA approved for relapsed and refractory HL and as post-ASCT consolidation in high risk patients. It is currently being actively tested in upfront and first salvage setting for patients with HL and DLBCL with promising activity. It is plausible to anticipate that, in the future, a higher percentage of relapsed and refractory HL or DLBCL patients would be BV-resistant and the importance of regimens effective in BVresistant disease is increasingly relevant. PD-1 (also termed PDCD1) blockade resulted in 65-87% ORR and 16-17% CR in patients with relapsed and refractory HL Armand et al, 2016) . Given the high tolerability and lack of overlapping toxicity, it would be of great interest to add PD-1 blockade to the TEC regimen and examine its feasibility and efficacy. We showed that the T(R)EC regimen is an effective bridge to ASCT with high transplant realization rate in responders. Importantly, we did not observe negative impact on autologous stem cell mobilization and collection. This is consistent with in vitro data indicating that limited exposure to bendamustine has low toxicity on stem cells and is in line with our recent study, in which bendamustine, etoposide, and dexamethasone effectively mobilized PBSC in patients with multiple myeloma (Green et al, 2016) .
One apparent advantage of the T(R)EC regimen is that it can be safely delivered in the outpatient setting, making it appealing to both patients and providers. This is reflected in 12 of 14 enrolment sites on the study being from community oncology centres. This is unlike most early phase I/II clinical trials conducted in a single academic centre, probably reflecting a more real-world, reproducible patient population and care setting. Hospitalization occurred in only 9 (19%) patients due to treatment-related complications. This is in sharp contrast to conventional multiagent chemotherapy regimens such as RICE, DHAP (dexamethasone, high dose cytarabine, cisplatin), or ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin), all of which typically require hospitalization upfront for treatment administration. Our matched cost-comparison analysis showed that the cost of one cycle of T(R)EC regimen was similar to one cycle of (R) ICE or R-DHAP with most of the T(R)EC regimen costs due to chemotherapeutics and RICE/R-DHAP from hospitalization, not including hospitalization for complication management (Bodding-Long et al, 2015) . Once generics for bendamustine are available we would anticipate a major economic advantage favouring T(R)EC.
Our study indicates that the T(R)EC regimen is a safe and effective outpatient salvage option for transplant-eligible patients with relapsed or refractory DLBCL and HL. It provides the basis for prospective comparisons with historical regimens as well as a backbone for adding novel agents to further enhance response rate.
